Previous Nav
Net Change on 01-07-2022
PersonalFN Rating
Category
Assets (Cr.)
Expense Ratio
Fund House
Launch Date
Benchmark
Minimum Investment (₹)
Minimum Addl Investment (₹)
Exit Load (%)
Minimum SIP Investment (₹)
Minimum STP Investment (₹)
Minimum SWP Investment (₹)
52 Week Low Nav (₹)
52 Week Low Nav Date
52 Week High Nav (₹)
52 Week High Nav Date
Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised
Sun Pharmaceutical Industries Limited
Cipla Limited
Dr. Reddy's Laboratories Limited
Divi's Laboratories Limited
Torrent Pharmaceuticals Limited
Narayana Hrudayalaya Limited
Lupin Limited
Abbott India Limited
Aurobindo Pharma Limited
Fortis Healthcare Limited
Sanofi India Limited
Gland Pharma Limited
JB Chemicals & Pharmaceuticals Limited
Apollo Hospitals Enterprise Limited
Thyrocare Technologies Limited
Pfizer Limited
Zydus Lifesciences Limited
Triparty Repo
Indoco Remedies Limited
Alkem Laboratories Limited
Vijaya Diagnostic Centre Limited
Rainbow Childrens Medicare Limited
IPCA Laboratories Limited
Orchid Pharma Limited
Tarsons Products Limited
Ajanta Pharma Limited
Jubilant Pharmova Limited
Healthcare Global Enterprises Limited
Cash Margin - CCIL
Net Current Assets
Pharmaceuticals & Drugs
Hospital & Healthcare Services
Miscellaneous
Plastic Products
Cash
Equity
Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹4,515.92 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.
The NAV of Nippon India Pharma Fund ended up ₹2.17(0.83%)yesterday to ₹262.9609.
Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and
The Nippon India Pharma Fund is managed by Sailesh Raj Bhan and Kinjal Desai.
4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013